Mod GRF 1-29 & GHRP-2 Blend (10mg)


Size: 10mg
Contents: CJC-1295 NO DAC (Mod GRF 1-29) 5mg, GHRP-2 5mg
Form: Lyophilized powder
Purity: >99%

FREE Shipping on $200+ orders

FREE Bacteriostatic Water (30ml) on $200+ orders

Discount per Quantity

5 - 85%$65.55
9 +10%$62.10
SKU: P-MODGRFGHR2-10 Categories: , Tags: , ,


Mod GRF 1-29 & GHRP-2 Peptide Blend

GHRP-2 and Modified GRF 1-29 peptides are synthetic peptides developed with the intention to aid in synthesis, secretion, and regulation of growth hormones. These peptides appear to exert synergistic action when taken together as a blend. GHRP-2 is a synthetic peptide similar to ghrelin, a naturally occurring peptide.(1) Ghrelin is a peptide containing 28 amino acids that is considered by scientists to regulate growth hormones, appetite, and heal wounds.(2) Modified GRF 1-29 (or Mod GRF 1-29) is an artificial peptide analog to the naturally occurring growth hormone-releasing hormones (GHRH). Structurally similar to GHRH, the peptide contains a chain of 29 amino acids and is slightly modified for proposed durability by substituting a four amino acid-chain.(3) These two peptides have been studied for their potential to stimulate the pituitary cells, triggering the secretion of growth hormones. GHRP-2 appears to have additional modes of action where (i) it may bind with growth hormone release factor (GRF) receptors, (ii) may act on calcium channels and stimulate growth hormone release, and (iii) may trigger cAMP pathway and protein kinase C, which in turn may stimulate growth hormone release.(4)

Chemical Makeup(3,5)

Molecular formula:
Modified GRF 1-29 peptide: C152H252N44O42
GHRP-2: C45H55N9O6

Molecular weight:
Modified GRF 1-29 peptide: 3367.9 g/mol
GHRP-2: 818.0 g/mol

Other known titles:
Modified GRF 1-29 peptide:

  • CJC 1295 Without DAC
  • Mod GRF (1-29)


  • Pralmorelin
  • Growth hormone-releasing peptide-2

Research and Clinical Studies


Modified GRF 1-29 & GHRP-2 Peptide Blend and Body Systems

Several studies(6) have been carried out on animals to understand the various potential actions of this class of peptides promoting growth hormone synthesis and release. According to researchers, the presentation of the peptides in both guinea pigs and rabbits did not result in any profound action on the central nervous systems. The only reported change was seen was an increase in the motility rate of the isolated ileum of rabbits and increased muscle contractions in the isolated ileum of the guinea pigs. No other impacts were observed on the kidneys, respiratory, gastric, and blood systems. As per Furuta S et al., these results suggest that the peptide “has no serious general pharmacological effects at dose levels showing GH-releasing activity in the experimental animals. Therefore, it is concluded that the peptide will be a useful drug for diagnosing serious GH deficiency and treating short stature.” (6)

Modified GRF 1-29 & GHRP-2 Peptide Blend and Appetite

A clinical trial(7) was carried out in which seven male test subjects were observed. The subjects in the trial were divided into two groups – one of which was given the peptide, and the others were given a saline solution for approximately 5 hours. After peptide presentation, all subjects were taken to buffet-style meals to measure their food intake.  The peptide subjects ate approximately 35% more than the saline group, with each subject exhibiting increased appetite when measured against their body weight. Moreover, the concentration of growth hormone also appeared to increase significantly in the peptide test subjects.  These results indicate a possibility that one of the additional actions of the peptide blend may be increased food intake and appetite.

General Research in Growth Hormone Secretagogues (GSHs), Growth Hormone Releasing Peptides (GHRPs)

The key objective of these clinical studies(8) was to evaluate the potential impacts of growth hormone secretagogues (GSHs) and growth hormone-releasing peptides (GHRPs) are amongst test subjects. As part of the study, subjects were monitored for physiological changes after being presented with the peptide. After completing this study, the results suggested that these peptides appeared to yield an increased growth rate in younger subjects, increased appetite, and increased lean mass in mature subjects. In obese test subjects, these peptides appeared to stimulate a reduction in bone turnover, increased lean mass, and improved sleep cycle. The researchers stated that these peptides appear to “increase lean body mass, reduce fat mass, increase exercise tolerance and maximum oxygen uptake, enhance muscle strength, and improve linear growth.”(8)

Modified GRF 1-29 & GHRP-2 Peptide Blend and Growth Hormone Deficiency

Since 2000, several clinical studies have been conducted on test subjects possessing growth hormone deficiency. Subjects presented with peptides stimulating growth hormone release indicated that these peptides might produce their action in two ways, including (i) possibly stimulating the pituitary gland to release growth hormones and (ii) acting on the arcuate nucleus of the hypothalamus. While these peptides, including GHRP-2 and Modified GRF 1-29, appeared to yield high concentrations of growth hormones, it remains to be seen how they work. In addition, these studies suggested that these peptides may impact food intake, heart tone, and sleep cycle via receptor-specific agonistic actions.(9)

In a study focusing on young test subjects, six growth hormone-deficient subjects facing growth failure were presented with different concentrations of growth hormone-stimulating peptides for eight months.(10) All subjects were monitored for any significant rise in growth hormone levels and toxicity levels during this period.  Throughout the study, there appeared to be a steep rise in the levels of growth hormones in all subjects for the duration of the study and a little time after. As per V Mericq et al., the study suggested that the peptides were “well tolerated and [may] stimulate GH secretion.”

Modified GRF 1-29 & GHRP-2 Peptide Blend and Hormones

In one clinical study(11), the primary objective was to understand the impact of peptide presentation on growth hormones, cortisol, prolactin, and adrenocorticotropic hormone (ACTH) levels in male test subjects. All subjects were divided into two groups based on their age – the first group had six mature subjects aged between 22 and 27 years, and the second group had 6 mature subjects aged between 66 and 73 years. Both groups were presented with growth hormone release stimulating peptides like Mod GRF 1-29 & GHRP-2. While the growth hormone levels increased in both groups, the younger group was observed to have a significant increase compared to the elderly volunteers. These hormones also appeared to stimulate increased levels of ACTH and cortisol hormones and a mild increase in prolactin levels.  The results supported the hypothesis that these peptides may have profound hormonal secretion capabilities in both mature and young male test subjects.


Mod GRF 1-29 & GHRP-2 Peptide blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.




  1. Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging. [Updated 2019 Oct 7]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA):
  2. Phung LT, Sasaki A, Lee HG, Vega RA, Matsunaga N, Hidaka S, Kuwayama H, Hidari H. Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine. Domest Anim Endocrinol. 2001 Jan;20(1):9-19.
  3. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC.
  4. Roh SG, He ML, Matsunaga N, Hidaka S, Hidari H. Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells. J Anim Sci. 1997 Oct;75(10):2744-8. doi: 10.2527/1997.75102744x. PMID: 9331879.
  5. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 6918245, Pralmorelin.
  6. Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-80. doi: 10.1055/s-0031-1297042. PMID: 15646371.
  7. Laferrère, Blandine et al. “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” The Journal of clinical endocrinology and metabolism vol. 90,2 (2005): 611-4.
  8. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004
  9. Rogério G. Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283,
  10. Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998 Jul;83(7):2355-60.
  11. Emanuela Arvat, Lidia Di Vito, Barbara Maccagno, Fabio Broglio, Muni F Boghen, Romano Deghenghi, Franco Camanni, Ezio Ghigo, Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH, Peptides, Volume 18, Issue 6, 1997, Pages 885-891, ISSN 0196-9781,

NOTE: These products are intended for laboratory research use only. Mod GRF 1-29 & GHRP-2 blend for sale is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.